How do clinicians currently make treatment decisions for breast cancer?
In early stage invasive breast cancer, the most important issue is the likelihood of recurrence. The evaluation of the likelihood of recurrence is based on multiple factors, such as nodal status, tumor size, tumor grade, and ER (estrogen receptor), PR (progesterone receptor), and HER2 status, as well as the age of the patient. Currently, treatment decisions are based on the outcomes of many clinical trials, and on observations of large populations, which provide population-based probabilities of recurrence, but not an individual’s own risk. However, there is a significant unmet need: the ability to provide patients with quantitative, clinically validated predictors of the risk disease recurrence in the individual. Such information can help the patient make the best breast cancer treatment decisions. How would the OncotypeDX™ improve decision making? Oncotype DX™ is a tool that quantifies the likelihood of disease recurrence in women with early stage breast cancer and assesses the likel
Related Questions
- Can I give my patient advocate the authority to make decisions to withhold or withdraw life-sustaining treatment, including food and water administered through tubes?
- Can I give my patient advocate the right to make decisions to withhold or withdraw life sustaining treatment?
- How do clinicians currently make treatment decisions for breast cancer?
